Oncology Live CME Series: Innovative Care for Head and Neck Cancer: A 2024 Update of Changing Paradigms


Oncology Live CME Series: Innovative Care for Head and Neck Cancer: A 2024 Update of Changing Paradigms Banner

Add to Calendar Oncology Live CME Series: Innovative Care for Head and Neck Cancer: A 2024 Update of Changing Paradigms 4/10/2024 5:30:00 PM 4/10/2024 6:30:00 PM America/Los_Angeles For More Details: https://ucsd.cloud-cme.com/course/courseoverview?EID=2663 Description: This course will provide an overview of current and emerging therapies for head and neck cancers, including new treatment paradigms incorporating immunotherapy as well as new treatment standards for radiation therapy and surgical treatment. This will include specific discussion of integration and sequencing of therapies in a multidisciplinary care model. Topics discussed will include:Surgical therapy for... false MM/DD/YYYY


Date & Location
Wednesday, April 10, 2024, 5:30 PM - 6:30 PM

Target Audience
Specialties - General Surgery, Internal Medicine, Oncology, Otolaryngology-Head & Neck Surgery, Plastic Surgery, Primary Care, Radiation Oncology, Radiology
Professions - Advanced Practice Nurse, Dentist, Fellow/Resident, Industry Representative, Medical Assistant, Medical Student, Nurse, Other, Physician, Physician Assistant, Radiology Technician, Scientist / Researcher

Credits
AMA PRA Category 1 Credits™ (1.00 hours), ABS CC (1.00 hours), Non-Physician Attendance (1.00 hours)

Overview

This course will provide an overview of current and emerging therapies for head and neck cancers, including new treatment paradigms incorporating immunotherapy as well as new treatment standards for radiation therapy and surgical treatment. This will include specific discussion of integration and sequencing of therapies in a multidisciplinary care model.

Topics discussed will include:

  • Surgical therapy for oropharynx cancer.
  • De-escalation strategies for oropharynx cancer.
  • Alternatives to cisplatin for older and medically unfit patients with locoregionally advanced head and neck cancer.
  • Novel Therapeutics for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Objectives
Upon completion of this activity, learners should be able to:

  1. Identify the indications for primary surgical therapy for oropharynx cancer.
  2. Describe de-escalation strategies for oropharynx cancer.
  3. Summarize evidence supporting alternatives to cisplatin and the rationale for newer treatment strategies being tested in clinical trials.
  4. Review current best practices, about active clinical trials and emerging therapies in the pipeline for recurrent/metastatic head and neck cancer.

Registration


Registration is Free!

Registration must be completed by 5:00pm PT on April 10, 2024 in order to attend.

 


Accreditation
The University of California San Diego School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of California San Diego School of Medicine designates this Live Activity activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category 1 credit for completing this program.

Nurses: For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credits™ issued by organizations accredited by the ACCME. For the purpose of relicensure, the California Board of Registered Nursing accepts AMA PRA Category 1 Credits™ (report up to 1.00 hours of credit and list "CME Category 1" as the provider number).

Pharmacists: The California Board of Pharmacy accepts as continuing education for pharmacists coursework which meets the standard of relevance to pharmacy practice and is accepted as continuing education by the Medical Board of California.

Surgeons: Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME requirement of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.